SMTL ID : 6kpp.1

BNC105 in complex with tubulin

Coordinates
PDB Format
Method
X-RAY DIFFRACTION 2.75 Å
Oligo State
hetero-2-2-1-1-mer
Ligands
2 x GTP: GUANOSINE-5'-TRIPHOSPHATE(Non-covalent)
4 x MG: MAGNESIUM ION(Non-covalent)
2 x CA: CALCIUM ION(Non-covalent)
2 x DO6: (6-methoxy-2-methyl-7-oxidanyl-1-benzofuran-3-yl)-(3,4,5-trimethoxyphenyl)methanone(Non-covalent)
2 x GDP: GUANOSINE-5'-DIPHOSPHATE(Non-covalent)
2 x MES: 2-(N-MORPHOLINO)-ETHANESULFONIC ACID(Non-covalent)
2 x GOL: GLYCEROL(Non-functional Binders)
Links
RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP
Citation
Wang, T. et al., Unraveling the molecular mechanism of BNC105, a phase II clinical trial vascular disrupting agent, provides insights into drug design. Biochem.Biophys.Res.Commun. (2020)
Release Date
2020-08-19
Peptides
Tubulin alpha-1B chain: AC
Tubulin beta chain: BD
Stathmin-4: E
Tubulin tyrosine ligase: F
SMTL:PDB
SMTL Chain Id:
PDB Chain Id:
A
A
C
C
B
B
D
D
E
E
F
F

Tubulin alpha-1B chain

Tubulin beta chain

Stathmin-4

Tubulin tyrosine ligase

Related Entries With Identical Sequence

4i4t.1 | 4i50.1 | 4i55.1 | 4ihj.1 | 4iij.1 | 4o2a.1 | 4o2b.1 | 4o4h.1 | 4o4i.1 | 4o4j.1 | 4o4l.1 | 4tuy.1 | 4tv8.1 | 4tv9.1 | 4yj2.1 | 4yj3.1 | 4zhq.1 | 4zi7.1 | 4zol.1 | 5bmv.1 | 5c8y.1 | 5ca0.1 | 5ca1.1 | 5cb4.1 | 5eyp.1 | 5ezy.1 | 5fnv.1 | 5h74.1 | 5h7o.1 | 5itz.1  more...